SynthesisRevista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)
Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials.
Synthesis in Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Phytochemicals with potential NMDAR-inhibitory activities: a review of neuroprotective mechanisms against excitotoxicity.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- Targeting the BDNF/TrkB/CREB pathway: emerging strategies for neuroprotection in Parkinson's disease.Molecular biology reports · 2026Review
- Drugs with glutamate-based mechanisms of action in psychiatry.Pharmacological reports : PR · 2024Review
- Molecular docking, derivatization, characterization and biological assays of amantadine.Future medicinal chemistry · 2024Article
- Glutamate Receptors and C-ABL Inhibitors: A New Therapeutic Approach for Parkinson's Disease.Central nervous system agents in medicinal chemistry · 2024Review
- Metabolic profiling to evaluate the impact of amantadine and rimantadine on the secondary metabolism of a model organism.Scientific reports · 2023Article
- A Randomized, Open Label, Exploratory Trial Comparing Efficacy of Amantadine and Ropinirole in Restless Legs Syndrome.Sleep science (Sao Paulo, Brazil) · 2023Article
- Article
- Towards Modeling Anhedonia and Its Treatment in Zebrafish.The international journal of neuropsychopharmacology · 2022Article
- Tyrosinyl-amantadine: A New Amantadine Derivative With an Ameliorative Effect in a 6-OHDA Experimental Model of Parkinson's Disease in Rats.Journal of molecular neuroscience : MN · 2022Article
- Involvement of inflammatory responses in the brain to the onset of major depressive disorder due to stress exposure.Frontiers in aging neuroscience · 2022Review
- An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2021Review
- Toxicity of amantadine hydrochloride on cultured bovine cornea endothelial cells.Scientific reports · 2021Article
- Amantadine for the treatment of childhood and adolescent psychiatric symptoms.Proceedings (Baylor University. Medical Center) · 2021Article
- Movement as a Positive Modulator of Aging.International journal of molecular sciences · 2021Review
- Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.Journal of neural transmission (Vienna, Austria : 1996) · 2021Review
- Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression-Case Series Study.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Pharmacological Treatments for Patients with Treatment-Resistant Depression.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Regulation of BDNF-TrkB Signaling and Potential Therapeutic Strategies for Parkinson's Disease.Journal of clinical medicine · 2020Review
- A possible antiviral effect of amantadine in an AH1N1 influenza-infected patient - a case report.Anaesthesiology intensive therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAmantadine blocks N-methyl-D-aspartate (NMDA) receptors and has dopaminergic and noradrenergic action, a neurochemical profile that suggests its potential as an antidepressant drug. We conducted a systematic review of preclinical and clinical studies addressing the effects of amantadine in animal models of depression and in patients with depression.
methodsPubMed, Science Direct, and Web of Science were searched up to September 1, 2017 to identify clinical and preclinical studies. The following search terms were used: "amantadine AND depress*"; "amantadine AND mood"; "amantadine AND animal models AND antidepres*"; and "amantadine AND (forced swim, learned helplessness, reserpine, chronic mild stress, anhedonia, sucrose preference)."
resultsAmantadine had antidepressant-like effects in animal models and appeared to potentiate the antidepressant effects of other antidepressants. These preclinical findings have received some support from the results of small open-label clinical trials, suggesting that amantadine can reduce depressive symptomatology and potentiate the antidepressant effects of monoaminergic drugs. In addition to its glutamatergic and dopaminergic effects, the potential antidepressant-like effects of amantadine have been linked to molecular and cellular actions, such as increased expression of neurotrophic factors (e.g., brain-derived neurotrophic factor), activation of σ1 receptors, decreased corticosterone levels, and decreased inflammatory response to stress.
conclusionAmantadine is an interesting candidate as new antidepressant drug for the treatment of depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.